News

Frontline chemoimmunotherapy was associated with improved median overall survival, compared with chemotherapy alone, in patients with advanced non–small cell lung cancer.

Adverse experiences, such as smoking and experiencing physical abuse, do not necessarily decrease the frequency of colorectal cancer screenings.

Elizabeth R. Cullen, MSN, ARNP, talks severe oral mucositis management for patients with locally advanced head and neck cancer.

Maintenance bevacizumab plus durvalumab and olaparib improved progression-free survival in patients with HRD-negative advanced ovarian cancer.

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Oncology nurses do not have to be in positions of authority to demonstrate great leadership.

Glofitamab has received accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma.

Patients with relapsed/refractory multiple myeloma treated with elranatamab following any prior BCMA-directed therapy achieved an overall response rate of 46%.

Amanda McKaig, BSN-RN, OCN; and Alyssa Ridad, BSN-RN, OCN, discuss how Ryan’s Law has changed their practice and how oncology nurses have responded to the changes.

Omitting radiotherapy did not compromise overall survival rates for patients with primary mediastinal B-cell lymphoma.

Patients with ESR1 mutations who received 12 months or more of prior treatment with a CDK4/6 inhibitor achieved a median progression free survival of 8.61 months with elacestrant compared with 1.91 months for those given standard therapy.

Heather Niccum Haag, BSN, RN, CCRN, shares how her institution improved patient education with the treatment belzutifan.

Patients with HER2-positive, metastatic colorectal cancer derived clinical benefit from a 5.4 mg/kg dose of trastuzumab deruxtecan.

Sabrina Banegas, RN, BMT-CN, highlights the value of improving antibiotic administration times for patients undergoing bone marrow transplant.

Abbey Kaler, MS, APRN, FNP-C, CMSRN, demonstrated extraordinary oncology nursing by being a consistent champion of the patient’s voice.

Enfortumab vedotin plus pembrolizumab elicited durable responses in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.

Novel strategies for patient education can help to build trust in and decrease the fear of lung cancer screening among patients.

Meredith Cummings, BSN, RN, OCN, discusses the potential benefit of machine learning in predicting symptoms for patients with head and neck cancer.

According to investigators, digitized cognitive behavioral stress management may help clinicians offer more comprehensive cancer care.

Sacituzumab govitecan improved overall survival vs treatment of physician’s choice in pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.

Ciltacabtagene autoleucel improved progression-free survival vs pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with lenalidomide-refractory multiple myeloma.

Kara Morris, MSN, RN, OCN; and Christine Wylie, MSN, RN, OCN, discuss their research on oral cryotherapy as a mucositis mitigation strategy.

Debi Fischer, MSW, BSN, BA, LCSW, RN, walks through some cancer support groups that may be of interest to oncology specialists.

Adjuvant mRNA-4157, in combination with pembrolizumab, improved recurrence-free survival, and distant metastasis-free survival, for patients with high-risk melanoma.

Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP; and Tia Wheatley, DNP, RN, AOCNS, BMTCN, highlight the value of multidisciplinary approaches in hematopoietic stem cell transplantation care.

Phase 2 findings show that adding a tyrosine kinase inhibitor to dual immunotherapy curbed disease progression in patients with metastatic soft tissue sarcoma.

Numerical, but not statistically significant, improvements in survival were observed in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer who received pembrolizumab to pemetrexed and platinum-based chemotherapy.

Yelena Shames, MSA, ACNP-BC, CNRN, argues that frequent hematologic evaluations may not always be warranted with immune checkpoint inhibitors.

Sintilimab plus chemoradiotherapy was associated with better event-free survival rates in locally advanced nasopharyngeal carcinoma than chemoradiotherapy alone.

A 5-year analysis of the phase 3 KEYNOTE-426 trial showed continued benefit with pembrolizumab plus axitinib for patients with advanced treatment-naïve clear cell renal cell carcinoma.